Pale Fire Capital SE Has $621,000 Stock Holdings in Kura Oncology, Inc. $KURA

Pale Fire Capital SE trimmed its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 93.4% in the second quarter, HoldingsChannel reports. The firm owned 56,600 shares of the company’s stock after selling 800,874 shares during the quarter. Pale Fire Capital SE’s holdings in Kura Oncology were worth $621,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of KURA. IFP Advisors Inc raised its position in shares of Kura Oncology by 115.3% in the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after purchasing an additional 1,284 shares during the period. Royal Bank of Canada boosted its holdings in shares of Kura Oncology by 7.6% during the 4th quarter. Royal Bank of Canada now owns 19,577 shares of the company’s stock worth $203,000 after buying an additional 1,375 shares during the period. Allworth Financial LP boosted its holdings in shares of Kura Oncology by 59.9% during the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after buying an additional 1,553 shares during the period. Focus Partners Advisor Solutions LLC grew its stake in Kura Oncology by 7.9% in the 4th quarter. Focus Partners Advisor Solutions LLC now owns 22,889 shares of the company’s stock valued at $238,000 after buying an additional 1,682 shares during the last quarter. Finally, ProShare Advisors LLC grew its stake in Kura Oncology by 10.0% in the 4th quarter. ProShare Advisors LLC now owns 18,572 shares of the company’s stock valued at $193,000 after buying an additional 1,692 shares during the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on KURA. Wedbush raised their price objective on shares of Kura Oncology from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, August 13th. Raymond James Financial set a $24.00 target price on Kura Oncology in a research report on Monday, August 24th. Wells Fargo & Company set a $24.00 target price on Kura Oncology in a research note on Thursday, June 4th. Wall Street Zen raised Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Sanford C. Bernstein set a $24.00 price target on Kura Oncology in a research note on Monday, June 15th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.40.

Insider Buying and Selling

In related news, insider Brian T. Powl sold 4,345 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $11.89, for a total transaction of $51,662.05. Following the sale, the insider owned 169,269 shares of the company’s stock, valued at $2,012,608.41. This represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Mollie Leoni sold 84,929 shares of the firm’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total value of $834,002.78. Following the transaction, the insider owned 182,345 shares in the company, valued at approximately $1,790,627.90. This trade represents a 31.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 120,761 shares of company stock valued at $1,283,346. 7.60% of the stock is currently owned by corporate insiders.

Kura Oncology Price Performance

Shares of Kura Oncology stock opened at $13.11 on Thursday. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -3.89 and a beta of 0.44. Kura Oncology, Inc. has a twelve month low of $7.36 and a twelve month high of $13.90. The company has a 50-day simple moving average of $11.01 and a two-hundred day simple moving average of $9.75.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The firm had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. Analysts forecast that Kura Oncology, Inc. will post -3.23 EPS for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.